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 Abstract 
 
Amyotrophic Lateral Sclerosis (ALS), more commonly referred to as Lou Gehrig’s disease, is a 
progressively degenerative neuromuscular disorder affecting both the upper and lower motor 
neurons and preferentially affecting males in their forties to seventies. Although the pathology of 
ALS has been clearly elucidated elsewhere, the precise mechanisms by which the disease 
progresses and the means by which it is acquired are still poorly understood areas of medicine. 
Current genomic and proteomic studies in human and animal models have yielded exciting and 
promising new findings that may help elucidate this pathology. It is the purpose of this review 
article to discuss the most relevant proposed mechanisms in current medical literature available 
from NCBI’s PubMed database as well as to highlight past, present, and future pharmacologic 
intervention therapies which have experienced varying degrees of success. This is by no means 
an exhaustive assessment of the current literature available; however it should suffice as a 
thorough review of the most salient points of modern ALS research. 
 
Keywords:   ALS, Amyotrophic lateral sclerosis, mechanism, pathology, pharmacology 
 
Introduction 
 
Amyotrophic Lateral Sclerosis (ALS), more commonly referred to as Lou Gehrig’s disease, is a 
progressively degenerative neuromuscular disorder affecting both the upper and lower motor 
neurons and preferentially affecting males in their forties to seventies.1,2   Disease pathogenesis 
selectively destroys upper motor neurons (UMN) of the primary motor cortex and corticospinal 
tracts in addition to lower motor neurons (LMN) of the spinal anterior horns and pontomedullary 
nuclei.3  The destruction of these motor neurons results in a loss of coordination for voluntary 
movement, often manifesting in a combination of UMN symptoms including muscle spasticity, 
hyperreflexia, increased deep tendon reflexes, and appearance of immature reflexes such as 
Babinski sign in conjunction with LMN symptoms such as progressive weakness, muscle 
hypotonia and atrophy, fasciculations, dysarthria, dysphagia and eventually respiratory failure. 
Of these symptoms, respiratory failure provides the greatest danger to the patient, with 
complications including secondary bacterial pneumonia compromising patients within two or 
three years of diagnosis.2   While the initial manifestation of these symptoms is seemingly 
random in distribution, disease progression often follows along contiguous neuroanatomic tracts 
to varying degrees of severity. The resulting UMN and LMN symptoms spread at differing rates 
and manifest as a consequence of complex somatotopy, creating complex motor phenotypes that 
are a hallmark of the disease.4   
 
The disease can further be subdivided into separate categories based on the method of 
inheritance or the location of symptom onset.1 ALS can present either sporadically (sporadic 
ALS, SALS) or along familial lines (Familial ALS, FALS) with a greater incidence of sporadic 
cases in the United States.1,2,5  Furthermore, symptoms of neurodegeneration can be first noticed 
either in the extremities (so-called extremity onset ALS) or the tongue (bulbar onset ALS). 
Extremity onset ALS is a degeneration of motor neurons enervating the arms or legs of afflicted 
individuals and can first include localized fasciculations, stiffness, and weakness.1  Patients with 
affected upper limbs will notice difficulty completing tasks that require manual dexterity 
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whereas those with lower limb onset will notice irregularities in gate and a distinct dropped foot 
appearance.1  Disease progression is often less rapid in those presenting with extremity ALS than 
in bulbar cases. Those afflicted with bulbar onset ALS first notice difficulty speaking or 
swallowing, and symptoms quickly spread to the intercostal muscles and the diaphragm,1 posing 
serious respiratory risks that are the most frequent cause of death in ALS patients.2  
  
Lack of Consensus 
 
Presently there is a surprising lack of consensus among the medical community as to how to 
categorize familial versus sporadic ALS.5  In an international study among leaders in ALS 
research spanning Europe, India, Australia, and North America there were inconsistencies in 
how the distinction between the two categories were defined. While some felt the criterion for 
FALS should include first-degree relatives including parents or siblings, others felt the need for 
second-degree (such as first or second cousins) or even any family relationship to warrant the 
title FALS.5 This distinction goes beyond nomenclature, as the protocols for diagnosing the two 
subfamilies differs substantially. When asked for comment, participating neurologists claimed to 
conduct screens for likely candidate genes implicated in ALS more frequently in FALS rather 
than SALS cases an overwhelming 67.0% to 10.3%, respectively.5  
 
Further complicating the situation is the lack of clear and agreed upon mechanisms of disease 
progression among the medical community. To date there have been over twelve loci and eight 
genes6  proposed as causative agents for FALS and among them exist hundreds of variations. Not 
surprisingly, the data available on such a diverse field of study is vast, with a literary search 
conducted on NCBI’s PubMed database yielding close to 19,000 unique entries for amyotrophic 
lateral sclerosis. Searches were subsequently narrowed to include the terms “pathology” and 
“pharmacology,” resulting in 1,034 results. Of these, entries were broadly selected to represent 
unique aspects of the body of literature as a whole. It is the purpose of this review article to 
therefore discuss the most relevant proposed mechanisms in current medical literature as well as 
to highlight pharmacologic interventional therapies with demonstrated or potential future success 
in treating ALS.  
 
Suggestive Trends in Diagnosis 
 
Among the difficulties in treating patients with ALS is quickly and effectively confirming a 
diagnosis while ruling out other possible disease processes. Effective clinical indicators are 
contested on the grounds of validity due to an incomplete understanding of the disease 
mechanism however firm agreement can be reached with regards to symptomology. For this 
reason, studies assessing the validity of measuring tongue strength as a prognosticator of bulbar 
onset ALS have yielded strong statistical significance.7 The effective use of this technique can 
help serve as a valuable tool in early, noninvasive detection of bulbar onset ALS rather than 
waiting for more advanced symptoms such as dysarthria and dysphagia which, once evidenced, 
are already severe enough to strongly affect patient survivability. Of the patients whose tongue 
strengths were assessed and who later developed ALS, a statistically significant proportion 
deteriorated quickly regardless of site of onset, indicating a rapid spread of lower motor neuron 
degeneration is best marked by assessment of tongue strength.7,8  
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On the other side of the clinical spectrum are highly advanced technologic measurements using 
functional Magnetic Resonance Imagery (fMRI) to assess neuronal activation as a function of 
disease progression. Interestingly, analysis of these techniques suggests there is an observable 
signal change in cortical blood oxygen levels during tasks requiring motor control of the hand 
specifically in ALS patients as measured against controls.9   These changes reflect a 
neuroplasticity heretofore unknown in ALS patients, although limited to those with slowly 
progressing disease symptomology and present only in initial phases of the disease.10   Still, 
these findings suggest either that slow disease progression affords patients the time to reorganize 
their own somatotopy or, conversely, that because patients are able to demonstrate efficient 
neuroplasticity they are able to delay the progression of the disease.9  Whichever the conclusion, 
the proven use of fMRI to assess these neuronal rearrangements proves promising for future 
study.  
 
Not all advancements in the understanding of ALS have been noninvasive; attempts at isolating 
novel markers from cerebral spinal fluid (CSF) in order to obtain objective clinical markers for 
disease progression remain one of the forefronts of ALS research. Degeneration of the blood-
CSF barrier is observed in 46% of ALS patients11 and offers a suggestive area of clinical 
assessment. Still, markers of blood brain barrier impairment, blood-spinal cord barrier 
impairment, blood-CSF barrier impairment, neuroaxonal degeneration, oxidative stress, 
neurotransmission, inflammation, immune activation, and glial activation have not yet yielded 
clinically relevant information in the diagnosis of ALS.11,12   While many of these markers are 
present in cases of ALS, they are not exclusive to this disease and have as yet presented a unique 
and reproducible clinical profile.  However advancements have been made in other 
neurodegenerative diseases, with reductions in CSF cAMP and cGMP concentrations in 
Creutzfeldt-Jakob disease but not in ALS.12  
 
Disease Modeling 
 
Clinical presentations afford unique opportunities to track the progression of disease while 
occasionally affording the chance to test FDA-approved experimental drugs. However in the 
interest of discovery, safer, non-human models must be selected for study in order to fully 
elucidate disease mechanisms and assess pharmacologic intervention therapies. The gold 
standard in ALS research remains the SOD1-G93A transgenic mouse model for preclinical drug 
studies. G93A mice possess gain-of-function mutations in the Superoxide Dismutase (SOD1) 
gene that enhances the generation of damaging oxygen radicals by Cu,Zn Superoxide Dismutase 
(Cu,Zn SOD). These mutations accurately reflect symptoms present in human FALS patients13-15 
while also affording the luxury of working with a small, relatively short-lived animal model.  
 
More recently, Pembroke Welsh Corgis and Boxers with mutations in SOD1 have been proven 
to illustrate degenerative myelopathy and peripheral neuropathy that can serve as a potential 
spontaneous model for human ALS. Homozygous silent mutations in canine SOD1:c.118 are 
able to recapitulate symptoms seen in the human disease process14  and can therefore offer 
superior alternatives to the murine model with regards to surgical study and evaluation of 
pharmacologic intervention. SOD mutants of the species Caenorhabditis elegans have also been 
generated for invertebrate study. C. elegans with pan-neuronal G85R SOD1 expression 
demonstrate significantly impaired locomotion and SOD1 aggregates characteristic of human 
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FALS patients with SOD1 mutations.15 These invertebrate models offer cheaper alternatives to 
the higher order research animals and are free of many of the ethical concerns present when 
working with mammals. They are limited in their application, though, as the Federal Food and 
Drug Administration requires drug testing to be performed on mammals before reaching the 
public.  
 
Proposed Mechanisms for ALS Pathogenesis  
 
Many of the proposed mechanisms currently under investigation focus on aberrations in neuronal 
transcription and translation events (Table 1). Irregularities in gene sequences either directly 
inherited or through predisposition to environmental insult, shift cellular machinery away from 
normal cellular chemistry toward dysfunctional proteins, hallmark cytosolic aggregations and 
plaques containing translationally inert RNA, and dysregulations in repair mechanisms. As no 
definitive etiology for ALS has been established, any or all of these mechanisms potentially 
represent processes in the pathology of disease and may contributes to a greater interwoven 
narrative.  The following mechanisms are listed from most well-understood to the least 
elucidated although there is significant overlap in their purported functionality.  
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Table 1: MAJOR GENE REGIONS IMPLICATED IN ALS PATHOLOGY  
Gene Region Normal Function Aberrant Form  Associated Pathology  ALS 
Prevalence  
Aberrant RNA Binding Proteins     
Chromosome 9 Open Reading 
Frame 72 (C9orf72) 
Hexanucleotide Repeat Expansion 
9p21 non-coding portion of 
C9orf72 
Hexanucleotide 
GGGGCC expansion 
Downregulation of alternatively spliced 
C9orf72 transcript and formation of aberrant 
nuclear RNA foci 
40% FALS 
7% SALS 
Transactive Response DNA-
Binding Protein of 43 kDa (TDP-
43) 
Transcriptional repression; 
pre-mRNA splicing, 
stabilizing, and transport; 
translational regulation 
Silent mutations in 
342–366 loci 
Alternate RNA splicing sites, aberrant 
cytosolic aggregates 
5% FALS 
1% SALS 
Fused in Sarcoma (FUS) Presumed neuromuscular 
junction functionality  
Numerous variations 
in expression 
(overexpression, 
deletion) 
Disruptions in locomotion, abnormalities in 
neuromuscular junction functionality  
5% FALS 
1% SALS 
ATAXIN2 CAG-Repeat mRNA translational and 
stress response regulator  
>31 CAG repeats  Corresponding elongated polyglutamine 
moieties 
<1% FALS 
5% SALS 
Ewing Sarcoma Breakpoint Region 
1 (EWSR1) 
Putative transcriptional 
repressor, RNA binding 
protein 
Predicted C-terminal 
prion domain 
Aberrant cytosol localization, prion-like 
aggregation 
Unknown 
FALS 
<1% SALS 
Other Implicated Proteins     
Cu/Zn Superoxide Dismutase 1 
(SOD1) 
Destruction of superoxide 
radicals 
apoSOD1 
(hyperoxidized 
variant)  
Decreased O-glycosylation with β-N-
Nacetylglucosamine (O-GlcNAc), alteration 
in cellular phosphorylation, disruption of 
zinc reserves and altered zinc homeostasis  
20% FALS 
3% SALS 
Optineurin (OPTN) Golgi complex exocytosis, 
possible member of 
TNFα/NF-κB signaling 
pathway 
Novel deletions and 
missense mutations in 
300 bp Alu repeat 
sequences 
Inhibition of endosomal recycling, 
dysregulated control of cell death, abnormal 
cytosolic inclusion bodies, absent inhibition 
of NF-κB signaling pathway activation 
<1% FALS 
<1% SALS 
P56S Vesicle Associated membrane 
Protein associated Protein B 
(VAPB) 
Sphingolipid metabolism  Proline to serine 
substitution 
Nuclear envelope deformity, irregularities in 
nucleoporin and emerin delivery  
<1% FALS 
<1% SALS 
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Transactive Response DNA-Binding Protein of 43 kDa (TDP-43)  
 
TDP-43 is a nuclear nucleic acid binding protein primarily involved in RNA translational events 
and metabolism that when irregularly aggregated in the cytosol represents the major pathological 
finding in ALS cell studies.16-18   Pathologic accumulations demonstrate polyubiquination, 
hyperphosphorylation, and irregular cleavage that likely contributes to the abnormal localization 
in affected neurons. Once in the cytosol, mutant low molecular weight TDP-43 forms β-pleated 
sheets not consistent with wild type phenotype19 that are highly dependent on C-terminal 
domains demonstrating unusual stability and resistance to proteasome degradation.20   Granule 
accumulation is further promoted by microtubular dysfunction.21   Silent mutations in the 342–
366 region affect RNA splicing regulation promoting the formation of stress granules whose 
exact function is as yet poorly understood. Current research as to whether these aggregates are 
protective or the hallmark of cellular damage are currently under investigation, as are studies to 
determine  whether a loss of function or a gain of function mutation is responsible for this 
phenotype. What is known is that a polyubiquinated TDP-43 aggregate is present in 5% of FALS 
and 0.5-2% of SALS cases.22  
 
Regional differences in composition of TDP-43 stress granules between neuronal and glial 
intracytoplasmic inclusions in the spinal cord and medulla oblongata of SALS patients and those 
found in the basal ganglia and hippocampus indicate the possibility of heterogeneity in function 
or pathology depending on location in the central nervous system. Among these heterogeneities 
is the presence of Smurf2, an upstream effector of E3 ubiqitin ligase that may impact lower 
motor neuron function23 and studies suggesting TDP-43 operates independently of adenosine 
deaminase on RNA 2 (ADAR2).24  
  
It has been implicated that other proteinaceous aggregates present during times of cellular strain 
serve as scaffolding for the formation of the cytosolic TDP-43 aggregates.25   These aggregates 
may follow a prion-disease-like pathology of replication, acting as an infectious transmissible 
protein species that behaves as a template for misfolding of nascent wild type proteins.19,26,27  
This theory is further supported by the presence of described prion-related glutamine/asparagine 
(Q/N) rich domain preferentially seen in prion disease and also expressed in proteins in ALS 
patients with mutant TDP-43. Introduction of these proteins in human embryonic kidney 293 
(HEK293) cells was able to demonstrate prion seed-like behavior, serving as a template from 
which nascent wild type proteins misfolded to mutant conformations.19,28   Further studies in 
murine models with inducible cytosolic TDP-43 aggregates showed statistically significant 
correlation between increasing number of aggregates and ALS symptomatology, with a reversal 
of these symptoms seen on restoration of wild type TDP-43 function.29  
 
Work in C. elegans models has suggested TDP-43 aggregates serve as a nidus for calcium-
dependent neurodegeneration based on activation of killer aspartyl proteasomes. These models 
illustrate that reductions in intracellular calcium release, specifically via loss of function 
mutations in calreticulin, calnexin, or the ryanodine receptor or the introduction of intracellular 
calcium via ethylene glycol tetraacetic acid or dantroline are neuroprotective while increases in 
intracellular calcium via thapsigargin further exacerbate neurotoxicity.30  Other mouse studies 
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mimicking nascent TDP-43 function in deficient cell lines was able to produce similar findings, 
with poly(A)-binding protein nuclear 1 protein specifically demonstrating promising results.18,31  
 
TDP-43 has been tentatively linked to a mechanism involving C9orf72 hexanucleotide expansion 
and Fus due to their involvement in RNA binding and transport32 although these mechanisms are 
as yet poorly understood. Data co-localizing TDP-43 with FUS aggregates and not with SOD1 
has also been presented.21   Continued study into the pathogenesis of these aggregates is 
ongoing,33,34  but is made more difficult with inconsistencies in the expected phenotypes of 
genotyped individuals. In a study by Mosca et al. two blood relatives with identical genotypes 
for the TDP-43 locus evidenced markedly different phenotypes; one sibling had severe onset 
ALS whereas the other (and the two other heterozygotes in the family) remained unaffected.35  
Additionally, TDP-43 aggregates may not inherently be pathologic, having been located in 
adrenal medulla samples of individuals with and without ALS.36  Studies have begun elucidating 
the possibility that there are potential variations in TDP-43 conformations that can act as strains 
in pathogenesis with varying impact on cellular toxicity and disease pathogenicity.19 
 
Cu/Zn Superoxide Dismutase 1 (SOD1)   
 
Mutant SOD1 proteins have been implicated in extracellular neuronal damage in a number of 
central nervous system diseases and are the traditional model for ALS disease progression. 
Intracellular damage is seen in clinical preparations however there is an equally likely 
mechanism depicting extracellular neuronal damage in mutant of SOD1 totaling over 140 
variants. Studies have implicated that one of these variants, apoSOD1, undergoes abnormal 
folding to expose its zinc binding site,37 depleting cellular zinc stores and disrupting zinc 
homeostasis. In vitro studies have proven that apoSOD1 expression reduces viability of target 
cells but that this is not caused by the accumulation of cell aggregates as was seen in the RNA 
binding proteins listed previously. Further illustrating the zinc hypothesis are results showing 
abatement of cell destruction by the addition of exogenous zinc and exacerbation by the addition 
of known zinc chelators.38  These misfolded SOD1 mutants are increasingly becoming the target 
for drug therapy39  due primarily to their speculated early involvement in a thorough and 
complex oxidative damage cascade. Monoclonal antibody experiments targeting these 
abnormally folded SOD1 mutants40  have already been demonstrated in murine and human 
tissues. 
 
The oxidative stress mechanism of nitrous oxide and other radical species put forth by 
proponents of the SOD1 theory of ALS pathogenesis are well documented in the literature41 and 
accommodates a wide variety of SOD1 mutants with an equally wide array of cellular effects.42  
Among these varieties is a hyperoxidized variant of SOD1 found to be linked directly to certain 
cases of bulbar SALS43  as well as variants that resulted in decreased O-glycosylation with β-N-
Nacetylglucosamine (O-GlcNAc), an agent linked to competitive inhibition of cellular 
phosphorylation.44   The implication of this reduction in intracellular O-GlcNAc is a 
corresponding alteration in kinase activity which would cause highly irregular and cell-wide 
effects. Many of these mutants have phenotypic effects directly influenced by copy number of 
their aberrant proteins45  which are best assessed by RT-qPCR.  
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Similar to TDP-43 and its interrelatedness with Fus and C9orf72 hexanucleotide expansion, 
SOD1 mutations have been implicated in pathways with abnormal RNA binding proteins. 
Methodologies proposed by Pokrishevsky et al. purport TDP-43 or Fus aggregates in the cytosol 
facilitate wild type SOD1 conformational changes, forming new and unusual conformations.46  
This mechanism mirrors the already established pattern of prion diseases, where a misfolded 
protein serves as a template for further misfoldings.47   This theory is generally accepted among 
the ALS community as a likely mechanism to explain SALS with SOD1 abnormalities. SOD has 
also been implicated as an intermediate in the ER damage cascade, with mutant SOD1 
inappropriately utilizing PDI.48   To even further complicate the picture of a complete SOD1 
cascade, fibroblast growth factor 2 deficiency prolonged survival and improved motor 
performance in ALS mouse models positive for mutant SOD1 protein. Accompanying this 
deficiency was an associated up-regulation of glial derived neurotrophic factor and ciliary 
neurotrophic factor, two motor system-related neurotrophic factors.49  
 
Fused in Sarcoma (FUS)  
 
FUS is a nuclear RNA binding protein involved in transcription, post-translational modifications 
including RNA splicing and microRNA processing, and DNA repair.50-52   Aberrations in FUS 
also represent one of the primary hallmarks of ALS cellular pathology, identified in 4-6% of 
FALS and 0.7-1.8% SALS cases.53   These mutations result in a hyperosmolar cytosolic 
environment where localization of mutant aggregates can occur.51   These aggregates form stress 
granules similar to and occasionally co-expressed with TDP-43 and SOD1, where local RNA 
molecules play an as yet undetermined role in granule stability.54,55   Furthermore, FUS 
irregularities disrupt correct localization of RNA binding proteins, disrupting nuclear cellular 
events.56   One current theory posits the disruption in FUS localization prevents correct DNA 
damage repair, resulting in accumulation of injurious insults to motor neurons and culminating in 
stereotyped ALS symptomology.51   FUS mutants also express deficiencies in autoregulation, 
leading to an increased vulnerability to cellular stress and degeneration manifesting as axon 
withdrawal, synapse dysfunction, and muscular denervation.52  
 
Animal models in Drosophila have demonstrated that mutations in FUS analog Cabeza (Caz) 
causes in vivo toxicity by disrupting neuromuscular junctions and inducing apoptosis in motor 
neurons. These effects are caused by a gain in function mutation resulting in overexpression of 
the gene, although these effects rely on the expression of the protein in the nucleus. Mutations in 
the Drosophila homolog Caz caused retinal degeneration, wing defects, decreased viability, but 
most importantly locomotive impairment in motor neurons and a disruption of presynaptic 
terminals at the neuromuscular junction culminating in motor neuron apoptosis.57   Toxicity is 
directly correlated to a functional C-terminus with overexpression as well as deletion resulting in 
similar disruptions of locomotion and neuromuscular junction abnormalities seen in human ALS 
patients. Apoptosis of motor neuron cell bodies was only observed in FUS overexpression 
models.57   C-terminal FUS knockout mice have corroborated the evidence for cytosolic 
aggregation seen in Drosophila but were unable to recreate ALS symptomatology.58   Additional 
murine models have been able to demonstrate neuroinflammation, denervation of  neuromuscular 
junctions, reductions in functional dendritic cell architecture and total cell number, and 
premature host death when gain or loss of function mutations were introduced to FUS.59  
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Differences are observed in clinical models versus those seen in Drosophila, as variants in 
human FUS have been proven to signify endoplasmic reticular (ER) stress. Co-localization with 
ER markers was seen in human lumbar spinal cord sections taken from ALS patients. These 
markers include protein disulfide-isomerase (PDI) as well as calreticulin, whose aggregates were 
seen with FUS in motor neuron cytosols, having translocated from the nucleus. These findings 
were consistent with both SALS as well as FALS and are related to the pathophysiology of 
SOD1 mutations.48   Patient-derived induced pluripotent stem cells transformed into spinal cord 
neural cells represent one model of FUS study, where stress granule aggregation has been 
correlated to volume of cytosolic mutant FUS concentrations.60   Utilizing similar models, DNA 
damage has been linked to cytoplasmic accumulations of mutant FUS mediated by 
phosphorylation of its N terminus by the DNA-dependent protein kinase.61  
 
In contrast to the models discussing aberrant cytosolic inclusion as a means for pathology, forced 
nuclear aggregation of FUS has been able to demonstrate neuronal cell death in some in vitro 
models.62   One study has isolated nuclear mutant FUS aggregates from ALS fibroblasts that 
proved resistant to sodium dodecyl sulfate denaturation, supporting the possibility that there are 
multiple ways to alter FUS functionality to cause neurodegeneration.56   Similar to TDP-43, FUs 
has also been implicated in prion disease-like pathology with FUS stress granules serving as 
proteinaceous templates for misfolding of nascent FUS proteins.63-66   This area of study is not 
yet fully explored and represents an ongoing area of research. 
 
Chromosome 9 Open Reading Frame 72 (C9orf72) Hexanucleotide Repeat 
Expansion  
 
Repeats of the hexanucleotide GGGGCC within the non-coding portion of C9orf72 on 
chromosome 9p21 have been reported to cause chromosome 9-linked FALS and frontotemporal 
dementia (FTD)67  and represent the most common genetic variant of ALS.68   In an international 
cross-sectional study evaluating 4448 ALS patients, 37% of individuals with FALS are in 
possession of this mutation, having as many as 700-1600 copies of the repeat sequence compared 
to controls who only have 23 copies.69   Comparable studies have been conducted in French 
(46% FALS, 8% SALS),70   Italian (46% FALS),71  Greek (50% FALS, 8.2% SALS),72  Turkish 
(18.3% FALS, 3.1% SALS),73   Slavic (5.9% SALS),74   and Russian (15% FALS, 2.5% SALS)75  
populations testing positive for the GGGGCC repeat. Studies on Chinese SALS populations have 
yielded results indicating this sequence is not correlated to their patient populations, potentially 
describing a predilection for the C9orf72 hexanucleotide repeat for Caucasians.76,77   
 
Phylogenetic analyses suggest that the hexanucleotide first originated in Finland, with all present 
day GGGGCC sequences in C9orf72 owing to a single mutation event 1500 years ago and 
representing 46.4% of FALS and 21.1% SALS of the Finnish population.69,78   The 
hexanucleotide repeat leads to the downregulation of the expression of an alternatively spliced 
C9orf72 transcript and to the formation of aberrant nuclear RNA foci.70   The increasing 
evidence for the presence of this sequence in FALS cases combined with the late age of onset for 
symptoms has led some studies to evaluate the possibility that this irregularity in RNA 
processing caused by the hexanucleotide expansion may be initially corrected by conventional 
cellular repair mechanisms only to eventually overwhelm the system in later life.79   This 
expansion itself may not be inherently irregular but instead trigger pathogenicity in differentially 
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methylated states80,81  and has also demonstrated a concordance with abnormal localization of 
TDP-43, a hallmark of ALS neuronal pathology.68   Murine models with induced GGGGCC 
sequences have also been constructed, evidencing a gain of function relationship theorized 
elsewhere.82,83  
 
Although this sequence provides a possible marker for over one third of FALS cases, the ethical 
and moral implications of how to determine when patients should or should not be screened for 
this repeat are difficult at best to determine. The concerns about incomplete penetrance raised by 
Majounie et al. highlight an average age of disease onset of 57 with patients only beginning to 
have symptom onset well into their nineties.69   The exact determinants, if there are any, as to 
whether or not one should be screened for this repeat are as yet undetermined.84   Still, the screen 
can offer confirmation of disease in the event of a suspected diagnosis. Ongoing research into 
reproducible biomarkers of this region and novel therapeutic targets are a developing area of 
study.85  
 
P56S-vesicle-associated membrane protein-associated protein B (VAPB)  
 
VAPB is a type II integral membrane protein of the ER with the free N terminal region 
projecting into the cytosol and is involved in ER to Golgi transport as well as cellular stress 
response pathways.86-90   Murine models have illustrated loss of function mutations altering the 
unfolded protein response pathway, reducing functional myotubule formation91  and this model 
has been illustrated in human samples elsewhere.86,92   Additional murine studies have 
demonstrated progressive hyperactivity and motor impairment due to corticospinal and spinal 
motor neuron destruction in VABP transgenic mice.93   Autosomal dominant ALS based on a 
proline to serine substitution in the VAPB has been linked to nuclear envelope deformity, 
interrupting the transport of nucleoporin and emerin to the nuclear envelope.94   VABP has also 
been shown to suppress adipocyte lipid differentiation through alterations in mRNA expression, 
potentially altering energy metabolism in a subset of ALS patients.86   However, despite its 
involvement in intracellular transport, VABP mutations have not demonstrated alterations in 
protein transport or degradation.95   Of note, this mutation has not been demonstrated in SALS 
patients in Sweden, Portugal and Iceland.96  
 
Optineurin (OPTN) 
 
OPTN is a protein involved in the nuclear factor kappa B (NF-κB) signaling pathway. Several 
mutations have demonstrated inhibited NF-κB activation and irregular localization of NF-κB 
proteins to neuronal and glial cytoplasm97,98  with a 300 bp region consisting of Alu repeat 
sequences that are highly susceptible to novel deletions. Normal OPTN function has been shown 
to induce mitochondrial autophagolysosome formation and serves as an autophagy receptor, with 
mutations disrupting its ability to bind polyubiquinated proteins for transport to the lysosome for 
destruction.99-102   TDP-43 and SOD1 positive cells from SALS patients have also tested positive 
for OPTN mutations and suggest loss of function in OPTN as a contribution to TDP-43 
accumulation.97,103-105   OPTN mutants are especially prevalent in the Japanese population, 
constituting the second most mutated gene product associated with SALS in Japan.106  In contrast, 
this mutation is exceptionally rare in British populations where it is deemed unlikely to be 
pathologic107  but can serve as a potential cause of rare rapidly progressive SALS in the Dutch.108  
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 Ewing Sarcoma Breakpoint Region 1 (EWSR1) 
 
EWSR1 is a RNA binding protein related to FUS and TDP-43 and a member of the FET protein 
family. Due to the fact that this protein is in possession of a predicted prion domain located on 
the C-terminus, it is prone to aggregate formation in both in vitro and in vivo specimens. It has 
been demonstrated to have a toxic effect when expressed109  and was proposed as an additional 
candidate for ALS pathogenesis. Histologic preparations of ALS spinal cord specimens 
illustrated aberrant localization in the cytosol of EWSR1 as opposed to the nucleus in healthy 
controls.109-111   One study presented 817 patients with ALS and 1082 healthy control individuals 
who tested positive for mutations in EWSR1 exons 15-18, the most pathogenic mutations in the 
gene region.109,112   Further work is being conducted evaluating the relevance of this protein.  
 
Spinocerebellar Ataxia Type 2 Protein (ATAXIN2) 
 
ATAXIN2 is another RNA binding protein potentially linked to ALS pathology, with moderate 
expansion of CAG polyglutamine sequences correlating to increased risk of ALS.113  Based on a 
cohort of 1538 ALS patients and controls in one Italian study, polyglutamine sequences that in 
excess of 31 amino acids place an individual at elevated risks for SALS compared to those 
lacking the repeat sequence. These trends did not hold true for FALS cases.114   This was also 
demonstrated in a cohort study of 375 ALS patients of Sardinian ancestry with similar 
findings.115   Aberrant ATAXIN2 accumulations associate with TDP-42 and FUS, altering their 
respective cellular toxicities and serving as components of cytosolic ALS stress granule 
formation.113  
 
Epigenetics and Environment  
 
Recently, studies into the impact of environment on gene expression have yielded insight into the 
dynamic nature of transcriptional potential. Early life exposure, for example to in utero hypoxia, 
heavy metals, pesticides, tobacco, alcohol, or vitamin deficiency has been implicated as potential 
cause for changes in the genetic transcriptome.116-118   While the precise mechanisms by which 
such stressors can contribute specifically to ALS are as yet poorly understood, some promising 
studies have suggested specific methylation events on proteins such as Kir4.1 glial cell 
potassium channel by DNA methyltransferase may play a role in pathogenesis.119,120    
Additionally, individuals with specific single nucleotide polymorphisms in the MT gene 
encoding metallothionein have demonstrated environmental susceptibility to acquiring 
ALS.116,121 
  
Treatments and Interventions  
 
To date many studies have been conducted to determine which treatment interventions pose the 
greatest benefit to ALS morbidity and mortality. The following presents evidence for those 
methods that were strongly believed to be clinically significant, beginning with those that have 
demonstrable improvement on symptomatology and survival and continuing with interventions 
that may prove promising in the future, then concluding with several notable therapies that have 
not proven beneficial and should be avoided in the treatment of ALS (Table 2). Due to the 
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chronic nature of this disease, each intervention is part of a broader scope of treatment delivered 
by neurologists, respiratory therapists, speech-language pathologists, physical therapists, 
dieticians, social workers, psychiatrists, nurses, and other allied health professionals.  
 
 
Table 2: NOTABLE INTERVENTIONS TESTED IN MODIFYING ALS PATHOLOGY 
AND PATIENT QUALITY OF LIFE  
Intervention Impact on ALS Symptomatology  
POSITIVE INTERVENTIONS 
Bi-Level Intermittent 
Positive Pressure 
(BiPAP) 
Definitive, part of gold standard of treatment. Demonstrated 
prolonging lifespan and decreased symptom onset. Increase in mean 
survival by 14.2 months when used for four hours per day when 
FVC reaches 50% expected normal. 
Riluzole FDA approved for treatment of ALS. Neuroprotective, blocks CNS 
glutaminergic transmission though mechanism is still debated. 100 
mg daily dosing has increased one year survival 9% and increased 
mean survival by 3 months.  
Resistance Exercise Equivocal improvements in upper and lower extremity strength and 
quality of life measures.  
PROMISING INTERVENTIONS 
Arimoclomol Experimental. Presumed upregulation of heat shock factor-1 
resulting in correct SOD-1 folding.  
Ghrelin Limited studies have shown exposure in vitro block TNFα and IL-1β 
expression, possibly promoting motor neuron survival. 
Botox Clinical trials have shown decreases in upper esophageal sphincter 
hyperactivity and sialorrhea. 
Dextromethorphan with 
Quindine  
Phase I improvement in peduobulbar affect, not FDA approved for 
this use.  
FAILED INTERVENTIONS  
Nimodipine Calcium channel blocker proven to be ineffective in managing ALS 
symptoms in double blind study.  
Coenzyme Q10 (CoQ10) Speculated to counteract oxidative damage resulting in SOD mutant 
ALS due to role as mitochondrial antioxidant cofactor. Failed to 
demonstrate benefit in Phase II trials.   
Lithium Failed phase III multicenter double-blinded randomized control 
study, no discernible benefit to ALS patients. 
Minocycline Failed phase III multicenter double-blinded randomized control 
study, demonstrable harm illustrated for ALS patients. 
Erythropoietin Failed phase III multicenter double-blinded randomized control 
study, no discernible benefit to ALS patients. 
Bi-Level Intermittent Positive Pressure (BiPAP) 
 
Due to the current limited understanding of the full mechanism of disease progression in ALS, 
the most important treatment to date remains the effective administration of assisted respiratory 
technologies. Of these, the most useful and well-documented in the literature is the use of bi-
level intermittent positive pressure (BiPAP) as an effective, noninvasive, and generally well-
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tolerated means of ensuring gas exchange. In a retrospective study conducted at Hahnemann 
Hospital, Kleopa et al. evaluated the efficacy of BiPAP intervention on patient outcomes and 
noted significant success in prolonging lifespan and decreasing symptom onset in ALS patient 
populations. Furthermore, the clinic suggests that patients receive a recommendation for BiPAP 
during the first clinical visit where the Forced Vital Capacity (FVC) reaches 50% of the expected 
normal. When used for four hours a day or longer, BiPAP helped increase survival by 14.2 
months.122  
 
Riluzole  
 
Currently there is only one FDA-approved drug for the treatment of symptoms in ALS patients. 
This drug, Riluzole, is a neuroprotective drug that blocks glutamatergic neurotransmission in the 
CNS. It has been proven to inhibit the release of glutamic acid in vitro and in vivo, though the 
mechanism is still speculated and assumed to be due to inactivation of voltage-dependent sodium 
channels on glutamatergic nerve terminals or possibly the result of a G-protein coupled receptor 
cascade. Riluzole also blocks some of the postsynaptic effects of glutamic acid by 
noncompetitive blockade of N-methyl-D-aspartate (NMDA) receptors. The drug is generally 
accepted to be a neuroprotectant with strong anticonvulsant albeit sedative properties.123   In 
clinical trials, 100 mg daily dose of Riluzole was able to demonstrate a 9% gain in probability of 
surviving one year over control and raised median survival from 11.8 to 14.8 months. There was 
also modest symptom improvement in both bulbar and extremity onset ALS.124  
 
Dextromethorphan with Ultra Low-Dose Quinidine (Nuedexta®) 
 
Psuedobulbar affect is a prominent complaint among patients with ALS, prompting studies to be 
completed on the potential benefits of dextromethorphan. As a selective, noncompetitive 
antagonist of the N-methyl-D-aspartate subtype of the glutamate receptor studies initially 
attempted to determine if ALS symptomatology would be reduced although results showed no 
measurable decrease in rate of disease progression.125,126   In conjunction with ultra low dose 
quinidine to prevent rapid metabolism of dextromethorphan, Phase I studies have demonstrated 
improvement in peduobulbar affect. The most common side effects while taking 20 mg 
dextromethorphan and 10 mg quinidine although mild included light-headedness, slurred speech, 
and fatigue.127-129   Presently long term safety data is lacking.130,131   Due to difficulties 
extrapolating data from small sample sizes, this therapy is not yet FDA approved.  
  
Botulinum Toxin (Botox®) 
 
Botulinum toxin is a paralytic toxin that interferes with neural transmission by blocking release 
of acetylcholine, thus promoting muscle paralysis. In ALS patients suffering from upper 
esophageal sphincter hyperactivity and sialorrhea small clinical trials have demonstrated 
measurable increases in quality of life outcomes through botulinum administration.132-134  
Specifically, patients with UES hyperactivity experienced decreases in dysphagia for up to four 
weeks132  while sialorrhea was reduced for up to two months.133  
 
Resistance Exercise 
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With muscle weakness representing a significant cause of morbidity in ALS patients, 
surprisingly little objective data has been compiled on the effectiveness of resistance training in 
improving patient quality of life. Data remains largely equivocal due to existing cohort studies 
assessing small numbers of patients, but what data does exist is promising. One random 
controlled study determined improvement based on increased total ALS Functional Rating Scale 
as well as increases in upper and lower limb functionality and has been corroborated by studies 
undertaken in Canada.135-137   This is a promising area of study that will hopefully be developed 
more fully in the future.  
 
Arimoclomol 
 
Arimoclomol is an experimental research drug that amplifies heat shock protein gene expression 
during cell stress and has also been useful in prolonging the lifespan of SOD1 mutant mice. 
Although its exact mechanisms are poorly understood, it is assumed that Arimoclomol amplifies 
the active phosphorylated trimer of the transcription factor, heat shock factor-1. This could 
potentially increase available heat shock proteins to help chaperone the correct folding patterns 
in mutant SOD1 proteins.138   Efficacy studies are as yet unpublished for patients but the drug 
has proven to be well-tolerated and safe for human consumption at doses up to 300 mg/day with 
evidence strongly supporting the drug be dosed three times daily.139  
 
Ghrelin 
 
Studies from a Korean research team have recently begun utilizing ghrelin as a potential 
therapeutic treatment for ALS, based on the protective effect ghrelin has on motor neurons 
experiencing chronic glutamate excitotoxicity. Ghrelin has been implicated in the activation of 
extracellular signal-regulated kinase 1/2 and phosphatidylinositol-3-kinase/Akt/glycogen 
synthase kinase-3β pathways. In order to confirm ghrelin’s direct involvement in these cascades, 
spinal cord cultures were exposed to exogenous threohydroxyaspartate for three weeks in order 
to cause motor neuron degeneration. After this interval, application of ghrelin was able to 
significantly attenuate this degeneration. Ghrelin was also useful in preventing the expression of 
pro-inflammatory cytokines tumor necrosis factor-α and interleukin-1β, common factors in 
neurodegenerative inflammatory processes. From these studies, it is proposed that ghrelin is 
acting as a microglia deactivating factor, promoting the survival of distressed motor neurons.140  
 
Nimodipine 
 
Nimodipine is a calcium channel blocker unsuccessful in the therapeutic treatment of ALS that 
was theorized to potentially antagonize excitatory amino acid receptor activation, decrease 
calcium entry into damaged neurons, and slow or perhaps reverse ALS. Unfortunately in a 
randomized, placebo-controlled, prospective, double-blind crossover study of nimodipine 
therapy there was no statistical significance in the rate of decline of pulmonary function or limb 
strength during treatment compared to control. Additionally, subjects receiving nimodipine 
experienced associated side effects including diarrhea, nausea, and lightheadedness.141   
Researchers have abandoned this drug in ALS treatment and management at the clinical trial 
level, however one model utilizing SOD1(G37R) mice included nimodipine as part of a cocktail 
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including minocycline and riluzole and was able to demonstrate significant delay in symptom 
onset, preservation in muscle strength, and increased longevity.142  
 
Coenzyme Q10 (CoQ10) 
 
CoQ10 is an antioxidant and mitochondrial cofactor and as such serves as a promising 
pharmacologic intervention. SOD1 mutants suffer from oxidative damage, suggesting the 
addition of an antioxidant may improve the clinical scenario at least slightly, and the 
mitochondrial damage seen in some ALS specimens offered further hope that additional 
mitochondrial factors would abate symptoms. However, during Phase II testing 2,700 mg were 
administered daily for nine months and showed no statistically significant reason to continue on 
to Phase III testing. There were no observed side effects in the patient population taking CoQ10, 
however there were no observable benefits, either.143  
 
Lithium 
 
Lithium is a monovalent ion that chemically competes with magnesium to alter activity of 
glycogen synthase kinase-3 beta, inositol monophosphatase, and Akt/β-arrestin2. It represented a 
potential candidate drug for ALS disease modification due to its effects on cellular oxidative 
stress, inflammatory pathways, autophagy and neurotrophism.144   A trial study in 2008 ignited 
interest in lithium research for ALS when functional deterioration was markedly reduced in a 
cohort of 16 patients over a fifteen month timeframe. However meta-analysis of 1100 ALS 
patients using lithium was unable to reproduce these findings.145   Phase IIb randomized trials on 
67 patients and a phase III multicenter double-blinded randomized control study was concluded 
in 2011 that also was unable to demonstrate any significant benefit on survival outcomes.146,147   
Although clinical trials have heavily supported the notion that lithium is no longer a viable 
research prospect for the treatment of ALS, recent studies have demonstrated that co-
administration of riluzole may potentially mask potential neuroprotective effects of additional 
compounds, including lithium which in one trial was able to reduce ALS neurotoxicity.148  
 
Minocycline 
 
Minocycline is a member of the tetracycline class of antibiotics that has demonstrated potential 
neuroprotective effects as a result of its specific anti-inflammatory mechanisms and regulation of 
apoptosis pathways.149,150   After safety trials were established for patient use along with riluzole, 
clinical trials were initiated and early magnetic resonance imaging of patients on minocycline 
showed chemical changes in the precentral gyrus and brainstem in ALS patients.151,152   A phase 
III multicenter double-blinded randomized control study was completed in 2007 studying 412 
ALS patients who were administered 400 mg minocycline daily. The results indicated 
minocycline was actually harmful to patients, conferring no beneficial effect for ALS morbidity 
or mortality while reducing quality of life.153,154  
  
Erythropoietin 
 
Erythropoietin (EPO) is a hormone responsible for regulation of red blood cell production and 
was studied in murine models as a potential disease modifying agent for ALS, initially 
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improving motor function and prolonging symptom onset in a dose-dependent fashion.155-157  
CSF studies revealed lower EPO concentrations in ALS patients compared to controls, 
prompting research into potential efficacy trials.158   Although safe and well-tolerated initial 
studies and suggesting potential reductions in neurodegeneration, a phase III multicenter double-
blinded randomized control study of 208 patients was unable to demonstrate change in the course 
of ALS pathology.159-161  
 
Future Work 
 
At present there exists no cure or long-term treatment regimen for ALS. Lifespans are 
lengthened on an order of months with the most optimistic of therapies and the mechanism of 
disease pathogenesis at the cellular level is poorly understood. Promising studies on the use of 
autologous bone marrow mononuclear cells162  have been proven to reduce TDP-43 aggregations 
in limited study populations and lumbar intraspinal injection of neural stem cells163  have proven 
safe for continued Phase II research but as yet show no motor neuron protection. In addition to 
such exciting findings there are also disheartening discoveries still in their infancy. One proposed 
explanation for the failures of pharmacologic therapy has been an upregulation of ABC drug 
transporter proteins such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) 
both at mRNA and protein levels as seen in the SOD1-G93A mouse model.164   This research 
clearly illustrates that a cellular resistance mechanism is being utilized to some degree and 
presents its own set of unique challenges in future treatment strategies. 
 
Conclusion 
 
This has been an attempt at summarizing the most significant findings found presently in the 
literature regarding ALS disease progression, mechanism, and treatment. With the rapidly 
advancing rate of clinical trials and cytologic analysis there will invariably be discoveries that 
contribute to and potentially contradict many of the mechanisms proposed. At present the stress 
granule theory implicating the RNA binding proteins TDP-43, SOD1, and FUS are the most 
heavily implicated in ALS cellular pathology and riluzole is the only FDA approved 
pharmacologic intervention proven effective for disease modification and increased quality of 
life. Non-pharmacologic interventions such as physical therapy and BiPAP still present useful 
adjuncts to therapy and should be considered when treating ALS patients. As research continues 
to find new and more effective methods of treating ALS, these cellular pathways will become 
better known and serve as the foundation for improved therapies and increased survival for 
patients in the future.  
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